JointHealth™ express August 15, 2013
Let BCPharmaCare hear “Your Voice” on adalimumab
Here is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Adalimumab (Humira®) is now being considered for coverage under BC PharmaCare’s Your Voice program. BC PharmaCare is looking for your contribution to their medication review process for adalimumab (Humira®). Adalimumab is used to treat children with polyarticular juvenile idiopathic arthritis (pJIA). The medication is taken via subcutaneous injection and is administered every other week. The recommended dose depends on the height and weight of the child. Your input as patient, caregiver, and/or patient group is essential to a full and fair review of the medication.
You can give input if you are a B.C. resident and have pJIA, a caregiver to someone with pJIA or if your group represents people who live with pJIA. By filling out a questionnaire on a website called Your Voice, you can provide feedback to British Columbia’s Ministry of Health about adalimumab (Humira®).
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
Alternatively, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide your input to us by Wednesday, August 28 so that we may submit the questionnaire in time for the deadline.
Let BCPharmaCare hear “Your Voice” on adalimumab
Here is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Adalimumab (Humira®) is now being considered for coverage under BC PharmaCare’s Your Voice program. BC PharmaCare is looking for your contribution to their medication review process for adalimumab (Humira®). Adalimumab is used to treat children with polyarticular juvenile idiopathic arthritis (pJIA). The medication is taken via subcutaneous injection and is administered every other week. The recommended dose depends on the height and weight of the child. Your input as patient, caregiver, and/or patient group is essential to a full and fair review of the medication.
You can give input if you are a B.C. resident and have pJIA, a caregiver to someone with pJIA or if your group represents people who live with pJIA. By filling out a questionnaire on a website called Your Voice, you can provide feedback to British Columbia’s Ministry of Health about adalimumab (Humira®).
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
It is an opportunity for you to share your perspectives on medication decisions that affect you or someone you provide care for.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for adalimumab: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)
Alternatively, you can email us your input at feedback@jointhealth.org or call us at 604-974-1366. We can send it as a patient group on your behalf. Please provide your input to us by Wednesday, August 28 so that we may submit the questionnaire in time for the deadline.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.